Study: NCT00481832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 4 gm /m² IV over 2 hours on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: 1.5 mg/kg/d, IV from day -11 to -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5mg/kgbid,variable, po or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Description: Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD34+ Cells
Description: 2 x 10e6 CD34+ cells per kg actual body weight on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol
Description: 1 mg/kg, Day-11 to Day-7